What is King Pharmaceuticals's enterprise value?

King Pharmaceuticals (KG) reported enterprise value of $198.12M in Q1 2026.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.

King Pharmaceuticals KG Enterprise value

Enterprise value at other companies

Arch Capital GroupACGL

$34.82B-4.7%

Everest GroupEG

$13.12B-7.3%

SiriusPointSPNT

$2.21B+25.1%

Skyward Specialty Insurance Group, Inc.SKWD

$1.87B+51.3%

Selective Insurance GroupSIGI

$5.42B-16.3%

Tiptree Inc.TIPT

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Calculated from King Pharmaceuticals’s reported figures.

$83.6Mmarket cap+$176.7Mtotal debt−$62.2Mcash and equivalents=$198.12M

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's enterprise value?: King Pharmaceuticals (KG) reported enterprise value of $198.12M in Q1 2026.
What does enterprise value mean?: Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.